Key result
Low-dose luteolin fails to reduce doxorubicin-induced cardiovascular and pulmonary damage in rats.
Why the study?
The study aimed to evaluate the effect of luteolin on lung, heart, and aorta histology in rats subjected to doxorubicin-induced injury.
Does low-dose luteolin mitigate doxorubicin-induced cardiovascular and pulmonary injury in a rat model?
Does low-dose luteolin mitigate doxorubicin-induced cardiovascular and pulmonary injury in a rat model?
Low-dose luteolin (20 µg/kg) does not protect against doxorubicin-induced histological damage in the heart, aorta, and lungs of rats, suggesting higher doses or combination therapies are required.
Answers are grounded in this paper and cite their sources.
Low-dose luteolin offers no protection in this rat model; leaves open higher doses or combinations for doxorubicin cardiotoxicity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Şevgin et al. (2025) studied Doxorubicin-induced cardiovascular and pulmonary injury (n=34). Luteolin vs. Doxorubicin alone was evaluated on Histological assessment of cardiovascular and pulmonary damage. Co-administration of low-dose luteolin (/kg/day) failed to ameliorate doxorubicin-induced cardiovascular and pulmonary histological damage in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: